Company profilePharmaceutical#308 of 1,318 in Pakistan✓ No DRAP alerts

Bayer Pakistan Private Limited

Pharmaceutical company · 57 brands · 63 molecules

Ranked #9 of 58 companies in Skin Conditions

57 registered products 30 pharmaceutical brands 63 distinct molecules 0 DRAP alerts

Company overview

57
registered products
30
pharmaceutical brands
63
distinct molecules
12
therapeutic classes
0
DRAP alerts

Bayer Pakistan Private Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 57 product registrations across 63 distinct molecules. Its portfolio is concentrated in Skin Conditions and Anti-Infectives. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Bayer

78 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

21
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
20252
202618
Longest without revision

Top molecules by brand count

Therapeutic classes

Skin Conditions · 7Anti-Infectives · 7Hormonal Contraceptives (Combination) · 5Hormone Regulators · 4Diagnostic Agents · 4Antineoplastics · 3Gastro · 2Drugs For Treatment Of Bone Diseases · 1Cancer · 1Oestrogens · 1Anti-Parkinson Drugs · 1Cardiac Care · 1

Conditions treated

Eczema/Psoriasis/Dermatitis · 4Hormonal Therapy · 4Fungal Infection · 3Infection/Allergy · 2General Infections · 2Colic/Constipation · 1Hypertension · 1Oral Agents · 1Ulcer/Reflux/Flatulence/Acidity · 1Conventional Agents · 1Malaria · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official17 products · Rs 116.48 – Rs 124,754.64
DVAGO13 products · Rs 55.9 – Rs 8,900.08
Servaid27 products · Rs 117.58 – Rs 2,915.8
Median across source: Rs 355.31

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BAYER SCHERING PHARMA. holds 2 molecules not in this portfolio
IusLevonorgestrel
ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 146 molecules not in this portfolio
AlbuterolAmikacinAminophyllineAmlodipineAmlodipine BaseAmmonium Chloride
MASS PHARMA (PRIVATE) LIMITED holds 120 molecules not in this portfolio
000 I.UAcitretinAcitretin UspAmikacinAmlodipineAmlodipine Usp

Get the full profile for Bayer

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.